Luo Yu-qi, Ma Xiao-jing, Hao Ya-ping, Pan Xiao-ping, Xu Yi-ting, Xiong Qin, Bao Yu-qian, Jia Wei-ping
Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital; Shanghai Clinical Center for Diabetes; Shanghai Key Clinical Center for Metabolic Disease; Shanghai Diabetes Institute; Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China.
Acta Pharmacol Sin. 2015 Dec;36(12):1497-502. doi: 10.1038/aps.2015.81. Epub 2015 Nov 16.
Osteocalcin is involved in the progression of nonalcoholic fatty liver disease (NAFLD) in animal models and humans. In this study we investigated the relationship between serum osteocalcin levels and NAFLD in postmenopausal Chinese women.
A total of 733 postmenopausal women (age range: 41-78 years) with normal blood glucose levels were enrolled in this cross-sectional study. Women taking lipid-lowering or anti-hypertensive drugs were excluded. Serum osteocalcin levels were assessed using an electrochemiluminescence immunoassay. The degree of NAFLD progression for each subject was assessed through ultrasonography. The fatty liver index (FLI) of each subject was calculated to quantify the degree of liver steatosis.
The median level of serum osteocalcin for all subjects enrolled was 21.99 ng/mL (interquartile range: 17.84-26.55 ng/mL). Subjects with NAFLD had significantly lower serum osteocalcin levels (18.39 ng/mL; range: 16.03-23.64 ng/mL) compared with those without NAFLD (22.31 ng/mL; range: 18.55-27.06 ng/mL; P<0.01). Serum osteocalcin levels decreased with incremental changes in the FLI value divided by the quartile (P-value for trend<0.01). The serum osteocalcin levels showed a negative correlation with the FLI values, even after adjusting for confounding factors (standardized β=-0.124; P<0.01). Binary logistic regression analysis identified an individual's serum osteocalcin level as an independent risk factor for NAFLD (odds ratio: 0.951; 95% confidence interval: 0.911-0.992; P=0.02).
Serum osteocalcin levels are inversely correlated with NAFLD in postmenopausal Chinese women with normal blood glucose levels.
在动物模型和人类中,骨钙素参与非酒精性脂肪性肝病(NAFLD)的进展。在本研究中,我们调查了绝经后中国女性血清骨钙素水平与NAFLD之间的关系。
本横断面研究共纳入733名血糖水平正常的绝经后女性(年龄范围:41 - 78岁)。排除正在服用降脂或抗高血压药物的女性。采用电化学发光免疫分析法评估血清骨钙素水平。通过超声检查评估每个受试者的NAFLD进展程度。计算每个受试者的脂肪肝指数(FLI)以量化肝脏脂肪变性程度。
所有纳入受试者的血清骨钙素中位数水平为21.99 ng/mL(四分位间距:17.84 - 26.55 ng/mL)。与无NAFLD的受试者(22.31 ng/mL;范围:18.55 - 27.06 ng/mL;P<0.01)相比,患有NAFLD的受试者血清骨钙素水平显著降低(18.39 ng/mL;范围:16.03 - 23.64 ng/mL)。血清骨钙素水平随FLI值按四分位数增加而降低(趋势P值<0.01)。即使在调整混杂因素后,血清骨钙素水平与FLI值仍呈负相关(标准化β = -0.124;P<0.01)。二元逻辑回归分析确定个体血清骨钙素水平是NAFLD的独立危险因素(比值比:0.951;95%置信区间:0.911 - 0.992;P = 0.02)。
在血糖水平正常的绝经后中国女性中,血清骨钙素水平与NAFLD呈负相关。